“Our findings highlight the real-world impact of targeted therapies on population-level outcomes and underscore the urgent need for care models that ensure accessibility, affordability, and long-term sustainability in the era of precision oncology.”
Multiple myeloma is the second most common blood cancer in the United States and has long been considered a difficult disease to treat. For decades, treatment options were limited, and survival remained poor. However, the therapeutic landscape has changed dramatically over the past several decades with the introduction of stem cell transplantation, targeted drugs, immunotherapies, and more recently, CAR T-cell therapy and bispecific antibodies.
A research paper titled “Targeted therapeutics and U.S. population-level mortality trends in multiple myeloma: A SEER-based analysis from 1975 to 2023” was published in Volume 17 of Oncotarget. In this study, the researchers examined how these major treatment advances have coincided with changes in multiple myeloma mortality across the United States over nearly five decades. The study was led by first and corresponding author Navkirat Kahlon from the Mass General Cancer Center at Wentworth-Douglass Hospital in Dover, New Hampshire.
Looking Back at Nearly Fifty Years of Progress
To understand how multiple myeloma outcomes have evolved over time, the researchers analyzed mortality data from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program between 1975 and 2023. Using Joinpoint regression analysis, they evaluated age-adjusted mortality rates and identified periods during which mortality trends changed significantly.
Rather than examining individual clinical trials, the study looked at population-level mortality patterns and compared them with the timing of major therapeutic advances. Although this type of analysis cannot prove that new treatments directly caused changes in mortality, it can reveal whether improvements in survival occurred alongside the introduction of new therapies.
From Limited Treatment Options to Targeted Therapies
The earliest years of the analysis reflected an era when treatment options were largely restricted to alkylating agents and corticosteroids. During this period, population-level mortality from multiple myeloma increased steadily.
The first sustained decline in mortality appeared during the mid-1990s, coinciding with the adoption of high-dose chemotherapy followed by autologous stem cell transplantation. Over the following decades, additional improvements paralleled the introduction of several new therapeutic classes, including: Proteasome inhibitors, Immunomodulatory drugs (IMiDs), Monoclonal antibodies, Selective inhibitors of nuclear export (SINEs), CAR T-cell therapies, Bispecific antibodies.
Each successive wave of therapeutic innovation expanded treatment options and improved disease control for patients with multiple myeloma.
Mortality Declined as Treatment Options Expanded
The analysis identified several distinct periods in U.S. mortality trends.
Between 1975 and 1994, mortality increased significantly.
From 1994 to 2002, mortality began to decline following the introduction of autologous stem cell transplantation.
Between 2002 and 2009, mortality declined more rapidly during the period when proteasome inhibitors and immunomodulatory drugs entered routine clinical practice.
After a brief plateau between 2009 and 2014, mortality resumed declining from 2014 through 2021, coinciding with expanded use of monoclonal antibodies, maintenance therapy, and combination treatment strategies.
The most striking finding occurred during 2021–2023, when investigators observed the steepest decline in mortality across the entire study period, with an annual percent change of −5.64%. This period overlapped with the introduction of BCMA-directed CAR T-cell therapies and bispecific antibodies into clinical practice.
A New Era of Precision Immunotherapy
One of the major themes emerging from the study is how treatment for multiple myeloma has shifted from broadly acting chemotherapy toward increasingly targeted therapies.
Modern treatments act against myeloma cells through multiple mechanisms. Some inhibit the cellular machinery that cancer cells rely on for survival, others stimulate the immune system to recognize malignant plasma cells, while newer cellular therapies genetically engineer a patient’s own immune cells to target proteins expressed on myeloma cells.
These advances have transformed multiple myeloma from a disease with limited therapeutic options into one that can often be managed through multiple sequential lines of treatment, extending survival for many patients. The authors suggest that the cumulative effect of these therapeutic innovations likely contributed to the long-term decline in population-level mortality observed in the study.
Progress Brings New Challenges
Although survival has improved substantially, the researchers emphasize that important challenges remain.
Multiple myeloma is still considered incurable for most patients, requiring long-term treatment that may continue for years. Many of the newest therapies are also associated with considerable financial costs, specialized administration, and potential long-term toxicities.
The authors note that access to these advanced treatments remains uneven, with geographic location, socioeconomic status, insurance coverage, and availability of specialized treatment centers influencing who can benefit from recent therapeutic advances. They argue that improving access and affordability will be essential if future survival gains are to be shared more equitably across patient populations.
Looking Ahead
The authors conclude that mortality from multiple myeloma has declined substantially over the past five decades, with population-level improvements occurring alongside successive waves of therapeutic innovation. Their findings suggest that advances such as stem cell transplantation, targeted therapies, monoclonal antibodies, CAR T-cell therapy, and bispecific antibodies have collectively reshaped the treatment landscape.
While additional research will be needed to determine the long-term impact of newer immunotherapies and to address challenges related to survivorship, treatment costs, and healthcare access, this study illustrates how sustained scientific innovation can translate into measurable improvements in outcomes at the population level. As new therapies continue to emerge, ongoing monitoring of real-world mortality trends will remain essential for understanding how advances in cancer treatment continue to shape long-term outcomes for patients with multiple myeloma.
Click here to read the full research paper published in Oncotarget.
_______
Oncotarget is an open-access, peer-reviewed journal that has published primarily oncology-focused research papers since 2010. These papers are available to readers (at no cost and free of subscription barriers) in a continuous publishing format at Oncotarget.com.
Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).
Click here to subscribe to Oncotarget publication updates.
For media inquiries, please contact media@impactjournals.com.
